Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial-Reference-Cited by-同舟云学术

Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial

Published:2019-03-28 Issue:5 Volume:185 Page:874-882
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Becnel Melody R.¹^ORCID,Nastoupil Loretta J.¹,Samaniego Felipe¹^ORCID,Davis Richard E.¹,You M. J.²,Green Michael¹,Hagemeister Fredrick B.¹,Fanale Michelle A.¹³,Fayad Luis E.¹,Westin Jason R.¹,Wang Michael¹,Oki Yasuhiro¹,Forbes Sheryl G.¹,Feng Lei¹,Neelapu Sattva S.¹,Fowler Nathan H.¹

Affiliation:

1. Department of Lymphoma/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA

2. Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX USA

3. Seattle Genetics Inc. Bothell WA USA

Funder

University of Texas MD Anderson Cancer Center

Celgene

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15843

Reference28 articles.

1. Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

2. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

3. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.

4. Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

5. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Non-hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-analysis;Recent Patents on Anti-Cancer Drug Discovery;2024-02

2. Advances in the treatment of relapsed/refractory marginal zone lymphoma;Frontiers in Oncology;2024-01-25

3. Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience;Oncology Research;2024

4. EXABS-223-IBCL Treatment Options for Marginal Zone Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2023-09

5. Marginal zone lymphoma: 2023 update on diagnosis and management;American Journal of Hematology;2023-08-21